Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (2165)	1/24/2009 10:24:56 AM
From: richardred	Respond to of 7265

Yes, I would agree. Most of big pharma is cash rich and small promising biotechs will find it hard to get new funding. IMO shareholders, if offered are more likely to sign off on a deal for quick cash at prices below highs in the couple years past.

To: Jack Hartmann who wrote (2165)	7/23/2009 12:00:08 AM
From: richardred	Read Replies (1) \| Respond to of 7265

Bristol-Myers to buy Medarex for $2.4 billion * On Wednesday July 22, 2009, 8:32 pm EDT By Ransdell Pierson NEW YORK (Reuters) - U.S. drugmaker Bristol-Myers Squibb Co (NYSE:BMY - News) late on Wednesday said it will pay $2.4 billion to acquire Medarex Inc (NasdaqGM:MEDX - News), a biotechnology company that has been helping it develop a promising treatment for melanoma since 2005. The agreed offer of $16 a share represents a 90 percent premium to Medarex's closing share price on Wednesday of $8.40 per share on Nasdaq. Bristol already owns a 2 percent stake in Medarex, through its four-year-old partnership with its neighbor in Princeton, New Jersey. The deal could help Bristol-Myers regain its stature as one of the world's leading players in the oncology market, and to develop treatments for immunologic conditions such as arthritis, lupus and psoriasis. Medarex has developed mice with human immune systems that are able to generate fully human antibodies that can be used as drugs. The two companies are developing one of the antibodies, called ipilimumab, as a treatment for patients in late stages of melanoma -- the most deadly form of skin cancer for which no highly effective treatments now exist. In three mid-stage clinical trials, 30 to 42 percent of patients with metastatic melanoma treated with the drug were still alive after two years, which Bristol-Myers said established a survival benefit. The companies are now conducting a larger late-stage trial, requested by U.S. regulators, designed to show an unequivocal survival benefit. "This deal will give us (full) rights to ipilimumab and broadly position Bristol-Myers for long-term leadership in biologics," said Bristol-Myers spokesman Brian Henry, referring to complicated biotech drugs that are typically given by injection. He said Medarex is testing 10 other drugs in clinical trials, some with other large drugmakers. "This deal clearly expands our opportunities in oncology and immunology," Henry said. (Reporting by Ransdell Pierson; Editing by Gary Hill and Carol Bishopric) finance.yahoo.com